CN102805879A - Preparation method for biogenic fluorinated porcine hydroxyapatite (FPHA) bone substitution material - Google Patents

Preparation method for biogenic fluorinated porcine hydroxyapatite (FPHA) bone substitution material Download PDF

Info

Publication number
CN102805879A
CN102805879A CN2012102544932A CN201210254493A CN102805879A CN 102805879 A CN102805879 A CN 102805879A CN 2012102544932 A CN2012102544932 A CN 2012102544932A CN 201210254493 A CN201210254493 A CN 201210254493A CN 102805879 A CN102805879 A CN 102805879A
Authority
CN
China
Prior art keywords
bone
hydroxyapatite
fpha
pha
biogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2012102544932A
Other languages
Chinese (zh)
Other versions
CN102805879B (en
Inventor
陈卓凡
张汉卿
陈泽涛
刘泉
陈馥淳
黄宝鑫
李志鹏
伍永昌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Honour Biotechnology Co Ltd
Original Assignee
陈卓凡
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 陈卓凡 filed Critical 陈卓凡
Priority to CN201210254493.2A priority Critical patent/CN102805879B/en
Publication of CN102805879A publication Critical patent/CN102805879A/en
Application granted granted Critical
Publication of CN102805879B publication Critical patent/CN102805879B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Materials For Medical Uses (AREA)

Abstract

The invention discloses a preparation method for a biogenic fluorinated porcine hydroxyapatite (FPHA) bone substitution material. The method comprises the following steps of: 1) sawing cancellous bone of the lower section of thighbone of swine adults into bone blocks, and drying for later use, wherein the cancellous bone of the lower section of the thighbone of the swine adults is used as a raw material; 2) heating the bone blocks and sintering in the air, cooling at room temperature, cleaning completely and drying to obtain porcine hydroxyapatite; 3) soaking the porcine hydroxyapatite in a fluorine-containing solution for 12 to 24 hours, taking out and drying; and 4) placing the porcine hydroxyapatite which is treated in the step 3) in aerobic environment, heating to 700 to 800 DEG C, heating for 2 to 3 hours, cooling, washing, drying, and grinding to obtain powder, namely the biogenic FPHA bone substitution material. According to the method, the thighbone of swine is used as the synthesis raw material, and the bone substitution material which is obtained after physical treatment and chemical fluoridation has a grid structure which is suitable for cell growth, contains an appropriate amount of fluorine, can meet the repairing requirement of clinical bone defect, or can be used as a cell scaffold to be applied to bone tissue engineering, and is wide in source, and low in price.

Description

Biogenic property is fluoridized the method for preparing of hydroxyapatite bone alternate material
Technical field
The present invention relates to a kind of method for preparing of fluoridizing the hydroxyapatite bone alternate material, relate in particular to the method for preparing that a kind of biogenic property is fluoridized the hydroxyapatite bone alternate material.
Background technology
Hydroxyapatite (Hydroxyapatite; Hereinafter referred HA) is the most basic inorganic constituents of organism osseous tissue; A lot of good characteristics are arranged; The similarity of HA and bone mineral composition for example can promote the Osteoblast Differentiation of stem cell, forms nervus vasculairs that strong bone-CaP biomaterial combination interface and guiding close on nature bone characteristic such as grow into.In medical domain, carrying out the people with materials such as phosphate, calcium salts is that the synthetic pure HA of chemical process once had more in the past and to use, like the filling of small amount of bone defect repair, bone cyst bone cavity, implant surface coating etc.Yet pure HA is used for sclerous tissues's displacement and comes with some shortcomings, and for example physical and mechanical properties is undesirable, fragility is big etc.; Especially compare with the biogenic property HA that occurs afterwards; Bone formation performance a little less than, thereby big limitations its application, replaced by biogenic property HA basically clinically at present.
Different with synthetic HA is; Biogenetic derivation HA is to be synthesis material with biological bone; Remove through physics or chemical method and wherein can cause the bone alternate material that obtains behind the Organic substance of human immunity rejection; Its main component is HA, and 3-D solid structure is very similar with nature bone, and contains minor inorganics such as distinctive Ca, Mg, Zn, Cl in the nature bone.Behind the HA bone alternate material of bone defect implantable bioartificial source; Its basis HA can be used as raw material and the space supporting structure in the new bone formation process; The measurements of the chest, waist and hips porous network structure is more conducive to that human body is osteoblastic to be adhered to and close on osseous tissue blood vessel, neural growing into, and it is more conducive to the formation of new bone and the reconstruction of bone-grafting material with the very similar constituent of nature bone.Therefore biogenetic derivation HA compares with synthetic HA in BFR, skeletonization amount and area of new bone quality and has absolute advantages, has become current bone-grafting material the most commonly used clinically.But the preparation quality of biogenetic derivation HA often is difficult to control, and the temperature of preparation is too low, and the organic principle in the biological bone is not divisible; The temperature of preparation is too high, the carbanion disappearance then can occur, and crystalline phase changes, and HA decomposes other materials of production.
The molecular formula of HA is Ca 10(PO 4) 6(OH) 2, Ca wherein 2+, PO 3-, OH -The position all can be substituted by different kinds of ions, so the scholar begins to explore some inorganic elementss that in HA, mix, thereby improves the physical and mechanical properties and the whole biological activity of material.Though have research to confirm, take in the excessive meeting of fluorine and cause toxic reaction.But; Fluorine is the trace element of needed by human, in the growth and development process of bone, tooth, plays an important role, and can promote the differentiation and the breeding of osteocyte; Promote crystalline formation of HA and growth; And the mineralising of sclerous tissues played a driving role, can improve sclerotin treatment osteoporosis thereby there is bibliographical information to increase the fluorion intake to a certain extent, so it receives much concern at aspects such as prevention of osteoporosis diseases.In cell culture experiments, find propagation and alkaline phosphatase activities that fluorion can stimulating osteoblast.Fluoridize the same raising of finding the osteoblast bone formation performance in the rat that water raises.Simultaneously, fluorine also has the effect of antibacterial bacteriostatic.Fluorination of drinking water is classified as one of 20th century ten big bus health achievement by U.S. disease prevention and control center at present; And obtain World Health Organization (WHO) and some other whole world and provincialism health and dentistry tissue affirm that Guangdong Province government has also proposed the project plan about the tap water fluoridize.
Existing research confirms that there is the group disappearance in the OH group among the biogenetic derivation HA in crystal, defectives such as dislocation arrangement.Wherein, the position of disappearance can be captured by fluorine, and the OH that dislocation is arranged is then substituted by fluorine more easily; The existence of these defectives has increased the alternate probability of fluorine, and F substitutes the OH group among the HA, and the dissolubility of apatite is reduced; Mechanical performance is improved; The ability that has releasing fluoride ion simultaneously makes it have stronger bone guided, inducibility and anti-microbial property, obtains good biology performance; Special more meaningful in the body fluid that only contains low dose fluoride, also be one of advantage of the synthetic FPHA of biogenetic derivation HA.It is abundant, cheap that biogenetic derivation HA synthetic method has the source, effectively simple; Avoid immunogenicity; And FPHA has kept the biological framework of HA, is retaining the more intravital favourable trace element of animal, and synthetic FPHA will more help growing into of osteocyte; Having stronger osteoinductive, is the developing direction of following preparation FPHA.
Yet; The technology of preparation biogenetic derivation HA is mainly grasped in foreign corporation's hands at present; And have only pure biogenic HA to drop into clinical use, China is domestic still not to have a homemade bone grafting bone alternate material, the biogenetic derivation HA of the many clinically employing imports the native land in; The Bio-oss that produces of Switzerland Co., Ltd for example, used biological collagen material is an Os Bovis seu Bubali.But the price of imported product is very expensive, and for example the purchase price of the Bio-oss of Switzerland Co., Ltd's production is 2000 yuan of every grams, and domestic patient will defray enormous cost and could use this product to treat.Thereby China needs a kind of biogenetic derivation HA that can substitute Bio-oss badly at present, to reduce patient's treatment cost.
In addition; Although existing research has proved that the disappearance position of OH group in crystal among the biogenetic derivation HA can be by the alternate principle of fluorine; Fluorine-containing bone alternate material is compared common biogenic HA in theory in many aspects and all had advantage, but still has a lot of indefinite technological blind spots during the HA of actual fabrication fluorion implantable bioartificial source, and is indeterminate like the material processed details; Detailed preparation process such as sintering bone piece position, size, form, temperature, heating rate etc. are difficult to learn optimum data; Academia does not still have clear and definite conclusion to fluorine implant concentration etc., and therefore, Shang Weijian has the technology report of fluoridizing biogenic HA bone alternate material.
Summary of the invention
The purpose of this invention is to provide a kind of biogenic property and fluoridize the method for preparing of hydroxyapatite bone alternate material, this method as synthetic raw material, is passed through the pig femur network that had both had suitable cell growth in the bone alternate material that is obtained behind physical treatment and the chemical fluoridize with the pig femur; And contain an amount of fluorine; Can satisfy the damaged reparation of bone clinically, or be applied to bone tissue engineer, have the national conditions of meeting again as cytoskeleton; Wide material sources, lower-price characteristic.
The object of the invention is realized through following technical scheme: a kind of biogenic property is fluoridized the method for preparing of hydroxyapatite bone alternate material, may further comprise the steps:
(1) draw materials: the femoral inferior segment spongy bone to become pig is a raw material, is sawn into the bone piece, drying for standby;
(2) sintering: to the bone piece sintering that heats up, temperature to be sintered rises to 700 ~ 900 ℃ under air atmosphere, and sintering is 1 ~ 2 hour under this temperature range, cleans up after the room temperature cooling then, and drying obtains Os Sus domestica hydroxyapatite (PHA);
(3) soak: the Os Sus domestica hydroxyapatite soaked in fluorine-containing solution 12 ~ 24 hours, took out drying;
(4) reacting by heating: will pass through Os Sus domestica hydroxyapatite after step (3) is handled and place and be warming up to 700 ~ 800 ℃ under the aerobic environment; And this temperature range internal heating 2 ~ 3 hours, cooling afterwash, drying; Pulverize obtains biogenic property and fluoridizes hydroxyapatite (FPHA) bone alternate material.
In the common animals, the similarity the highest (referring to table 1) of Os Sus domestica and people's bone.And the inventor discovers, the femoral inferior segment spongy bone of pig has the micropore that is suitable for cell growth, and simultaneously, its macroscopic mesh-like structure also helps flowing and perfusion of blood, and in preparation, spongy bone is beneficial to shaping, clinically also easy operating.Thereby the femoral inferior segment spongy bone that can adopt pig is as raw material.
Table 1: the similarity of animals and human beings bone
Os Canitis Os Caprae seu Ovis Os Sus domestica Os Leporis seu Oryctolagi
Macrostructure ++ +++ ++ +
Microstructure ++ + ++ +
Bone component +++ - +++ ++
Bone is rebuild ++ ++ +++ +
Annotate :+low similar, ++ moderate is similar, +++highly similar
But because the organic matter that biological bone contains can cause the intravital rejection of people, something must be done to when therefore using clinically removes fully.Find that after deliberation spongy bone is when 700 ℃ of left and right sides sintering, the organic matter in the bone almost can be removed fully; And be higher than 1000 ℃ high temperature sintering, just along with the difference of sintering time, decomposition in various degree takes place in HA; (β-TCP), its bone conductibility is weaker than HA, and absorption rate is fast than HA to produce tricalcium phosphate; Can influence the bone grafting effect, therefore, the sintering temperature of Os Sus domestica is controlled at 700 ~ 900 ℃.And Os Sus domestica HA mixes about 700 ~ 900 ℃ and does not almost have organic residual, no β-TCP and other unformed apatite among the FPHA that the fluorine sintering obtains after 1 ~ 2 hour; If but continue heating; Or temperature is too high; Then can cause the carbonate in the carbonated hydroxyapatite to decompose, temperature is crossed low or the too short fluorion of sintering time then is difficult to chemical mode and combines with PHA, can not reach the alternate purpose of fluorine.Therefore, in order to preserve this carbonate as far as possible, make it to preserve the advantage of biogenic property HA, the temperature of selecting 700 ~ 800 ℃ among the present invention is as the treatment temperature of step (4) reacting by heating.Both preserve carbonate, guaranteed the doping of fluorine again.
The volume size of the bone piece described in the step according to the invention (1) is 1 * 1 * 0.5cm 3, be beneficial to make in the subsequent step bone piece to be heated evenly, so that Organic substance is removed fully, fluorion is evenly implanted.
In the step according to the invention (1), the bone piece is at room temperature dry to get final product, and can not do other special handlings.As for improving the exsiccant efficient of bone piece, can adopt the mode of strengthening circulation of air to carry out drying.
The used in amounts of fluorine-containing solution satisfies the absorption requirement of PHA in the step according to the invention (3), normally adopts excessive Fluorinse to soak, and for example every 100ml Fluorinse soaks 1g PHA.The bone piece itself has loose structure, and Fluorinse did not have the bone piece can reach the even contact immersion.
Fluorine-containing solution in the step according to the invention (3) adopts sodium fluoride (NaF) solution, and the concentration of described Fluorinse is 0.25 ~ 1mol/L, is preferably 0.25 ~ 0.5mol/L.
Temperature is to rise to 700 ~ 900 ℃ from room temperature in the intensification sintering in the step according to the invention (2); The heating rate of temperature generally is advisable to be no more than 10 ℃/min; Cause Organic substance moment burning easily because heating rate is too fast, local temperature is too high, and the intermedium crystalline phase that causes being obtained changes.
Likewise, the heating rate of the heating-up temperature in the step according to the invention (3) generally is advisable to be no more than 10 ℃/min, avoids that heating rate is too fast to cause the burning of Organic substance moment to cause local temperature too high, prevents that the intermedium crystalline phase that is obtained from changing.
The drying that relates in step according to the invention (3) and (4) is being carried out below 80 ℃.
In step according to the invention (1) ~ (4), after drying, all need semifinished or finished goods be preserved at a distance from wet, avoid product to make moist, influence the result of use of semi-finished product at the treatment effect and the finished product of each step.
The present invention compared with prior art has following beneficial effect:
(1) the present invention is main synthetic raw material with Os Sus domestica, and its macrostructure, microstructure aspect are the most similar with people's bone, and the similarity of composition, bone density and people's bone is only second to Os Canitis., F obtains FPHA after substituting.Experiment confirm, this FPHA have kept the biological framework of HA, and are retaining the more intravital favourable trace element of animal; Compare with pure biogenic HA,, have stronger osteoinductive more helping growing into of osteocyte; New osteogenesis better effects if, range of application is more extensive, can better application in the damaged reparation of osseous tissue; The support of bone tissue engineer makes up, implant surface coating etc.
(2) the present invention is raw material with the Os Sus domestica, and is more extensive than Os Bovis seu Bubali, cheap in domestic its source of China; Help reducing the cost of raw material; And need not to take precautions against with Hinduism etc. is religious and conflict and medical-risk that bovine spongiform encephalopathy Os Bovis seu Bubali etc. brings, make application wider of product, simultaneously; Help simplifying preparation technology, thereby can reduce the cost of FPHA greatly.
For example; The Bio-oss that the Switzerland Co., Ltd of the import of using at present produces, its purchase price is 2000 yuan of every grams, and presses the Os Sus domestica of existing market valency purchase; Prepare according to the inventive method; Per 150 yuan Os Sus domestica can make 15g biogenic property FPHA, 100 yuan of its every gram cost less thaies, and selling price also can be far below the selling price of Bio-oss.It is thus clear that use of the present invention can fundamentally reduce patient's treatment cost, have sizable market competitiveness.
(3) to make the alternate FPHA of variable concentrations F, technology is very simple, is easy to realize the production of scale through the concentration of adjustment fluoride aqueous solution in the present invention.
(4) the present invention also can realize the cycling and reutilization of the Os Sus domestica of discarding in the past or only limiting to eat is turned waste into wealth.
Description of drawings
Below in conjunction with accompanying drawing the present invention is further specified, can understand structure and performance of fluoridizing biogenic property hydroxyapatite bone alternate material of the present invention better.
Fig. 1 is the following observed FPHA configuration of surface figure of the scanning electron microscope (SEM) of FPHA, and wherein A is SEM500 times, and B is SEM2000 times.
Fig. 2 is the following observed PHA configuration of surface figure of the scanning electron microscope (SEM) of PHA, and wherein A is SEM500 times, and B is SEM2000 times.
Fig. 3 is the following observed PHA configuration of surface figure of the scanning electron microscope (SEM) of contrast PHA, and wherein A is SEM500 times, and B is SEM2000 times.
Fig. 4 a is X-ray diffraction (XRD) figure, and wherein A is the FPHA group, and A heated is for soaking the PHA group, and B is PHA, and B heated is contrast PHA group, and C is artificial synthetic HA.
Fig. 4 b is X-ray diffraction (XRD) figure, and wherein A is the FPHA group, and A heated is for soaking the PHA group, and B is PHA, and B heated is contrast PHA group, and C is artificial synthetic HA.
Fig. 5 a is Fourier's infrared spectrum (FTIR) figure, and wherein, A is the FPHA group, and A heated is for soaking the PHA group, and B is PHA, and B heated is contrast PHA group, and C is artificial synthetic HA.
Fig. 5 b is Fourier's infrared spectrum (FTIR) figure, and wherein, A is the FPHA group, and A heated is for soaking the PHA group, and B is PHA, and B heated is contrast PHA group, and C is artificial synthetic HA.
Fig. 6 is the dissolubility that the solid titration method records PHA and HA.
Fig. 7 is the growing state sem photograph (SEM) of MG63 cell after cultivating three days on the FPHA sheet surface, and wherein A is the Electronic Speculum figure of 200 times of mirrors, and B is the Electronic Speculum figure of 1000 times of mirrors, and C is the Electronic Speculum figure of 2000 times of mirrors.
Fig. 8 is the different time propagation situation comparison diagram of MG63 cell on FPHA and PHA tabletting surface.
Fig. 9 is the different time cell viability comparison diagram of MG63 cell on FPHA and PHA tabletting surface.
Figure 10 is the micro-CT live body scanning three-dimensional reconstructed image of each processed group rat, and wherein, A was the 1st when week, and B is around the time, when C was the 8th week.
Figure 11 is the optical microscope figure under 50 times of mirrors of blank control group rat skull BIAO and BEN undecalcified sclerous tissues section, and wherein, the section of top is the section of the 4th all sclerous tissueses, and the section of below is the section of the 8th all sclerous tissueses.
Figure 12 is the optical microscope figure under 50 times of mirrors of PHA group rat skull BIAO and BEN undecalcified sclerous tissues's section, and wherein, the section of top is the section of the 4th all sclerous tissueses, and the section of below is the section of the 8th all sclerous tissueses.
Figure 13 is the optical microscope figure under 50 times of mirrors of FPHA group rat skull BIAO and BEN undecalcified sclerous tissues's section, and wherein, the section of top is the section of the 4th all sclerous tissueses, and the section of below is the section of the 8th all sclerous tissueses.
Figure 14 is the section of each processed group rat skull BIAO and BEN undecalcified sclerous tissues at 200 times optical microscope figure.
Figure 15 is each processed group rat Micro CT live body scanning area of new bone volume comparison diagram.
Figure 16 is each processed group rat Micro CT live body scanning area of new bone surface area comparison diagram.
The specific embodiment
Below set forth content of the present invention in further detail through embodiment and experimental example; But following embodiment just is used for content of the present invention is set forth; Rather than restriction; Therefore in implication suitable and any change in the scope, all should think to be included in the scope of claims with claims of the present invention.
Embodiment 1
(1) draws materials: get into pig femoral inferior segment spongy bone, remove most soft tissue, clean, be sawn into about 1 * 1 * 0.5cm of size 3The bone piece, drying at room temperature is subsequent use.
(2) sintering: variations in temperature in the bone piece sintering that in Muffle furnace, in air, heats up, programme-control stove rises to 800 ℃ with the heating rate of 10 ℃/min from room temperature; Kept sintering 2 hours at 800 ℃ then, take out after being cooled to room temperature, washed with de-ionized water once; Remove the residue on bone piece surface, filter 80 ℃ of dryings; Obtain Os Sus domestica hydroxyapatite (PHA), preserve at a distance from wet then.
(3) soak: in the ratio of every 100ml NaF solution soaking 1gPHA, get 1gPHA and be dipped in 100ml0.25mol/LNaF solution, let PHA be soaked in the excessive N aF solution, take out PHA behind the immersion 24h; All PHA preserve at a distance from wet in 80 ℃ of dryings.
(4) reacting by heating: will place clean Muffle furnace through the PHA that step (3) is handled; Under aerobic environment, carry out reacting by heating and handle, heating-up temperature is warming up to 700 ℃ with 10 ℃/min of heating rate from room temperature, and PHA keeps heating 3 hours in 700 ℃ of temperature then; Heat treated finishes the back taking-up and cleans 1min repeatedly with deionized water; Be milled into powdery after 80 ℃ of dryings, obtain biogenic property and fluoridize hydroxyapatite (FPHA) bone alternate material, preserve at a distance from wet.
Sample is carried out physicochemical property detect and zoopery, the result is referring to experimental example.
Embodiment 2
Different with embodiment one is:
(3) soak: in the ratio of every 100ml NaF solution soaking 1gPHA, get 1gPHA and be dipped in 100ml0.50mol/LNaF solution, let PHA be soaked in the excessive N aF solution, take out PHA behind the immersion 12h; All PHA preserve at a distance from wet in 80 ℃ of dryings.
(4) reacting by heating: will place clean Muffle furnace under aerobic environment, to carry out reacting by heating through the PHA that step (3) is handled and handle; Heating-up temperature is warming up to 750 ℃ with 10 ℃/min of heating rate from room temperature; PHA keeps heating 2.5 hours in 750 ℃ of temperature then, and heat treated finishes the back taking-up and cleans 1min repeatedly with deionized water, is milled into powdery after 80 ℃ of dryings; Obtain biogenic property and fluoridize hydroxyapatite (FPHA) bone alternate material, preserve at a distance from wet.
Sample is carried out physicochemical property detect and zoopery, the result is referring to experimental example.
Embodiment 3
Different with embodiment one is:
(3) soak: in the ratio of every 100ml NaF solution soaking 1gPHA, get 1gPHA and be dipped in 100ml0.75mol/LNaF solution, let PHA be soaked in the excessive N aF solution, take out PHA behind the immersion 20h; All PHA preserve at a distance from wet in 80 ℃ of dryings.
(4) reacting by heating: will place clean Muffle furnace under aerobic environment, to carry out reacting by heating through the PHA that step (3) is handled and handle; Heating-up temperature is warming up to 800 ℃ with 10 ℃/min of heating rate from room temperature; PHA keeps heating 2 hours in 800 ℃ of temperature then, and heat treated finishes the back taking-up and cleans 1min repeatedly with deionized water, is milled into powdery after 80 ℃ of dryings; Obtain biogenic property and fluoridize hydroxyapatite (FPHA) bone alternate material, preserve at a distance from wet.
Sample is carried out physicochemical property detect and zoopery, the result is referring to experimental example.
Embodiment 4
Different with embodiment one is:
(3) soak: by the ratio of every 100ml Fluorinse immersion 1gPHA, get 1gPHA and be dipped in 100ml1.00mol/LNaF solution, take out PHA after soaking 18h respectively; All PHA preserve at a distance from wet in 80 ℃ of dryings.
Sample is carried out physicochemical property detect and zoopery, the result is referring to experimental example.
Embodiment 5
(1) draws materials: get into pig femoral inferior segment spongy bone, remove most soft tissue, clean, be sawn into about 1 * 1 * 0.5cm of size 3The bone piece, drying at room temperature is subsequent use.
(2) sintering: variations in temperature in the bone piece sintering that in Muffle furnace, in air, heats up, programme-control stove rises 700 ℃ with the heating rate of 10 ℃/min from room temperature; Kept sintering 2.5 hours at 700 ℃ then, take out after being cooled to room temperature, washed with de-ionized water once; Remove the residue on bone piece surface, filter 80 ℃ of dryings; Obtain Os Sus domestica hydroxyapatite (PHA), preserve at a distance from wet then.
(3) soak: in the ratio of every 100ml NaF solution soaking 1gPHA, get 1gPHA and be dipped in 100ml 0.25mol/LNaF solution, let PHA be soaked in the excessive N aF solution, take out PHA behind the immersion 24h; All PHA preserve at a distance from wet in 80 ℃ of dryings.
(4) reacting by heating: will place clean Muffle furnace under aerobic environment, to carry out reacting by heating through the PHA that step (3) is handled and handle; Heating-up temperature is warming up to 800 ℃ with 10 ℃/min of heating rate from room temperature; PHA keeps heating 2 hours in 800 ℃ of temperature then, and heat treated finishes the back taking-up and cleans 1min repeatedly with deionized water, is milled into powdery after 80 ℃ of dryings; Obtain biogenic property and fluoridize hydroxyapatite (FPHA) bone alternate material, preserve at a distance from wet.
Embodiment 6
(1) draws materials: get into pig femoral inferior segment spongy bone, remove most soft tissue, clean, be sawn into about 1 * 1 * 0.5cm of size 3The bone piece, drying at room temperature is subsequent use.
(2) sintering: variations in temperature in the bone piece sintering that in Muffle furnace, in air, heats up, programme-control stove rises 900 ℃ with the heating rate of 10 ℃/min from room temperature; Kept sintering 1 hour at 900 ℃ then, take out after being cooled to room temperature, washed with de-ionized water once; Remove the residue on bone piece surface, filter 80 ℃ of dryings; Obtain Os Sus domestica hydroxyapatite (PHA), preserve at a distance from wet then.
(3) soak: in the ratio of every 100ml NaF solution soaking 1gPHA, get 1gPHA and be dipped in 100ml0.05mol/LNaF solution, let PHA be soaked in the excessive N aF solution, take out PHA behind the immersion 20h; All PHA preserve at a distance from wet in 80 ℃ of dryings.
(4) reacting by heating: will place clean Muffle furnace under aerobic environment, to carry out reacting by heating through the PHA that step (3) is handled and handle; Heating-up temperature is warming up to 700 ℃ with 10 ℃/min of heating rate from room temperature; PHA keeps heating 3 hours in 700 ℃ of temperature then, and heat treated finishes the back taking-up and cleans 1min repeatedly with deionized water, is milled into powdery after 80 ℃ of dryings; Obtain biogenic property and fluoridize hydroxyapatite (FPHA) bone alternate material, preserve at a distance from wet.
Embodiment 7
(1) draws materials: get into pig femoral inferior segment spongy bone, remove most soft tissue, clean, be sawn into about 1 * 1 * 0.5cm of size 3The bone piece, drying at room temperature is subsequent use.
(2) sintering: variations in temperature in the bone piece sintering that in Muffle furnace, in air, heats up, programme-control stove rises 750 ℃ with the heating rate of 10 ℃/min from room temperature; Kept sintering 2.5 hours at 750 ℃ then, take out after being cooled to room temperature, washed with de-ionized water once; Remove the residue on bone piece surface, filter 80 ℃ of dryings; Obtain Os Sus domestica hydroxyapatite (PHA), preserve at a distance from wet then.
(3) soak: in the ratio of every 100ml NaF solution soaking 1gPHA, get 1gPHA and be dipped in 100ml0.04mol/LNaF solution, let PHA be soaked in the excessive N aF solution, take out PHA behind the immersion 24h; All PHA preserve at a distance from wet in 80 ℃ of dryings.
(4) reacting by heating: will place clean Muffle furnace under aerobic environment, to carry out reacting by heating through the PHA that step (3) is handled and handle; Heating-up temperature is warming up to 750 ℃ with 10 ℃/min of heating rate from room temperature; PHA keeps heating 3 hours in 750 ℃ of temperature then, and heat treated finishes the back taking-up and cleans 1min repeatedly with deionized water, and 80 ℃ of dry backs are with being milled into powdery; Obtain biogenic property and fluoridize hydroxyapatite (FPHA) bone alternate material, preserve at a distance from wet.
Experimental example:
The sample that makes with embodiment 1 ~ 4 is an example, respectively it is carried out physicochemical property detection, cell in vitro detection, animal vivo test detection.Experiment component is that PHA group, contrast PHA organize, soak PHA group and FPHA group, and wherein the PHA group is the Os Sus domestica source property hydroxyapatite (PHA) that the present invention passes through the high temperature sintering preparation, and it is consistent with clinical biogenic HA composition commonly used to detect confirmation through experiment; Contrast PHA group is to carry out the PHA that reacting by heating is handled gained by preparing identical method with FPHA after soaking PHA with deionized water, and PHA group and contrast PHA group are all as testing reference with comparative evaluation FPHA physics and chemistry and biology performance; Soak that the PHA group is soaked in Fluorinse for PHA but the meso sample processed of sintering not, wherein contain certain density fluorion, but non-chemically implant, be soaked in the liquid and can separate out loss fast for physical absorption.
One, physicochemical property
PHA and FPHA with embodiment 1 ~ 4 are example, adopt SEM, XPS, and FTIR, XRD, EDS, TEM, micro-solid titration method is carried out the physicochemical property detection to the FPHA finished product of embodiment 1 ~ 4.Experiment component is PHA group, contrast PHA group, soaks PHA group and FPHA group, and the physicochemical property testing result is following:
1. morphology analysis:
Sample with embodiment 2 is an example, and like Fig. 1, the scanning electron microscope shown in 2 and 3 (SEM) testing result, pattern is similar substantially with FPHA for PHA, is loose porous space network; High power lens can be found the crystal grain of FPHA down for long bar-shaped, and form is more regular than PHA, and degree of crystallinity is higher, and the crystal grain of PHA and blank group is lamellar, irregular shape.
2. analysis of components:
According to X-ray microcell energy spectrum analysis (EDS) testing result, PHA and FPHA all mainly are made up of calcium, phosphorus and oxygen element, also contain a certain amount of carbon and Trace Sodium and magnesium.Its difference is, contains a certain amount of fluorine through the FPHA that fluoridizes gained.Composition is as shown in table 2 in detail.
Table 2:EDS half-quantitative detection PHA and FPHA composition
Figure BDA00001910864000101
3. crystalline phase analysis:
X-ray diffraction analysis (XRD) analysis result as shown in Figs. 4a and 4b, the X-ray diffraction peak of PHA and FPHA is similar, can be corresponding one by one with JCPDS72-1243 standard control card.Cause its lattice to shrink because fluorine is implanted PHA, degree of crystallinity increases, and the X-ray diffraction peak of experimental group FPHA is slightly to high angle of diffraction drift.
4. functional group analysis:
According to Fourier's infrared spectrum (FTIR) testing result, all contain carbonate group like Fig. 5 a and 5b among PHA and the FPHA, promptly this two be carbonated hydroxyapatite.In addition,, substituted part of hydroxyl, made that the absworption peak of hydroxyl disappears among the FPHA because fluorion is implanted in the PHA lattice.
5. fluorine chemistry state analysis:
The binding energy that shows fluorine among X line electron spectroscopy analysis (XPS) result reduces, and shows that variation has taken place its chemical state, and promptly its residing chemical micro-environment changes, changes in HA the state with calcium, phosphorus, the multiple interaction between atoms of oxygen into by Na-F.Concrete delta data is as shown in table 3.Wherein, C represents artificial synthetic HA; B represents PHA; The contrast PHA of B-heat representative after heat treated, the immersion PHA of 0.50mol/l Fluorinse has been soaked in A (0.50mol/l) representative, and A-heated (0.50mol/l) has represented through the immersion of heat treated the FPHA of 0.50mol/l Fluorinse; The immersion PHA of 1.00mol/l Fluorinse has been soaked in A (1.00mol/l) representative, and A-heated (1.00mol/l) has represented through the immersion of heat treated the FPHA of 1.00mol/l Fluorinse.
Table 3: laboratory sample XPS testing result
Group Fluorine element peak value (eV) Constituent content (%)
C - 0
B - 0
B-heated - 0
A(0.50mol/l) 685.09 3.61
A-heated(0.50mol/l) 684.38 2.10
A(1.00mol/l) 685.71 4.23
A-heated(1.00mol/l) 685.05 3.82
6. dissolubility
The most situation of bone-grafting material all are to be applied in to need the spatial zone of long term maintenance bone grafting clinically at present, can not absorb or absorb slowly bone-grafting material and be first and select, and when carrying out bone grafting in the aesthstic district of the upper jaw, recommend to use to absorb bone-grafting material slowly.Promptly concerning bone-grafting material, the bone alternate material of low solubility has greater advantages.Adopt the solid titration method to measure the dissolubility of PHA and HA, as shown in Figure 6, the PHA dissolubility is lower than HA, is about 1/4th of HA, explains that the PHA absorption rate can be lower than HA.And having document to confirm, the phosphorus ash stone crystal is replaced the back dissolubility at the OH group by F can further be reduced, so FPHA also has suitable advantage aspect dissolubility.
Visible from above-mentioned physicochemical property experimental result, the PHA sample of embodiment 2 is consistent with clinical biogenic HA composition commonly used, and main component is HA, contains the inorganic constituents that a small amount of natural bone tissue has simultaneously; The FPHA finished product is merely the fluorion chemical replacement and replaces the OH group gained among the PHA, and other material compositions do not change, and have the physicochemical property of fluoridizing hydroxyapatite.And the high temperature sintering condition of embodiment 1 ~ 4 is identical, and the heat treated temperature is close, and the FPHA performance of therefore final gained is close, all has the physicochemical property of fluoridizing hydroxyapatite.Below select the FPHA finished product of embodiment 1 to experimentize, verified the bone formation performance of the FPHA finished product of gained of the present invention.
Two, the release of the sticking of cell, propagation, differentiation and fluorine
Experimental apparatus
Artificial intelligence's tube type resistance furnace SGM6812BK, Luoyang, Henan, China
ZP10A rotary tablet machine Tianjin good fortune unit inscription instrument and equipment company limited, China
GM-2 type cobalt-60 gamma irradiation device Beijing gamma new and high technology company limited, China
Electronic balance ME235S, Sartorius, Germany
Superclean bench Kendrol, Germany
CO2 constant temperature incubator Shel Lab, the U.S.
Axiovert40 inverted microscope Zeiss, Japan
Electric heating constant temperature air dry oven DHG-9420A, Shanghai, China
Constant water bath box Shel Lab, the U.S.
Ultra-pure water cleaning system Millipore, Elix, the U.S.
Enzyme-linked immunosorbent assay instrument Tecan, Australia
Tabletop refrigerated centrifuge Kendro, the U.S.
QUANTA200 environmental scanning electron microscope FEI Company, Holland
Adjustable pipette Eppendrof, Germany
0.22 μ m filter Millipore, the U.S.
Ionic-activity meter L2850765, the Western Regions are dynamo-electric, Shanghai, China
Magnetic stirring apparatus IKA, Germany
Fluoride ion selective electrode Shanghai Russell, China
Saturated calomel electrode Shanghai Russell, China
Deionized water machine
Figure BDA00001910864000121
; Sartorius, Germany
Experimental technique:
1. the FPHA finished product with embodiment 1 is an example, with its compacting in flakes, obtains the FPHA sheet, and (Porcine hydroxyapatite, PHA) sheet is as negative control with biogenetic derivation hydroxyapatite that not fluorine-containing Os Sus domestica spongy bone makes.At each group tabletting surface seeding MG63 cell, use the growing state of scanning electric mirror observing cell, and utilize CCK-8 and ALP test kit to measure cell quantity and the ALP expression of inoculation back in the time of the 3rd, 7,10 day behind the γShe Xianmiejun on the tabletting surface.The result is like Fig. 7, shown in 8 and 9.
The scanning electron microscope of Fig. 7 shows; The MG63 cell is as the active cell of a kind of judge biomaterial commonly used, after FPHA tabletting surface is cultivated three days, and MG63 cell queueing discipline; Form is fusiformis or similar round; The size basically identical meets the form of normal person's osteosarcoma MG63 cell line, be inoculated in the FPHA surface after upgrowth situation good.
Mensuration result to 3,7,10 days each time point ability of cell proliferation sees Fig. 8; The OD value that FPHA and PHA respectively organize cell had tangible growth from 3 days to 7 days; Change not obvious and compared the OD value with 7 days in 10 days; Prompting MG63 cell strain propagation situation on the FPHA tabletting meets the growth curve of MG63 cell strain, is exponential phase of growth at 3 ~ 7 days promptly, gets into plateau after 7 days.In each time point, the average OD value of FPHA group cell climbing speed is high slightly than the PHA group, explains that adherent cell enlargement speed is higher than PHA on the FPHA tabletting, and FPHA promotes cell increment effect to be better than PHA, and grows with time, and difference is more remarkable.
Mensuration result to 3,7,10 days each time point emiocytosis ALP sees Fig. 9; The result shows: the ALP value that FPHA and PHA respectively organize emiocytosis all has rising from growing with time, and FPHA group cytoactive all is higher than the PHA group in each time point, and along with prolong observing time; The PHA group is different increasing with FPHA group OD value difference; Prompting MG63 cell strain cytoactive on the FPHA tabletting is higher than PHA, and along with the growth of time, cytoactive difference is more remarkable.
In sum, FPHA is more having superiority than PHA aspect human body cell adhesion, propagation, differentiation and the expression.
2. measure the fluor releasing quantity that in DMEM low sugar acid medium, soaks dissolving back FPHA and PHA tabletting respectively with the fluorion activity meter.
Table 4: the fluor releasing quantity (unit: μ g) of tabletting in acid medium
3 days 7 days 10 days
FPHA 43.1±0.9 32.1±1.6 28.1±2.3
PHA 20.0±1.2 22.2±1.7 29.1±0.8
Shown in the table 4, along with the increase of fluorinion concentration, the negative logarithm of fluorinion concentration reduces gradually, and the absolute value of equilibrium potential also reduces thereupon.FPHA and PHA tabletting record the equilibrium potential of each solution and see table according to the corresponding fluorinion concentration that regression equation Y=0.1068X-2.8344 obtains after the dissolving fully in acid medium; It is thus clear that the burst size of the fluorine that records as the PHA of negative control is trace very, almost can ignore.
Table 5: the equilibrium potential that tabletting records after in the neutral culture medium of DMEM low sugar, soaking 3,7,10 days (mean ± standard deviation, mV)
Equilibrium potential (mean ± standard deviation, mV) -lgF-(ppm) F-(ppm)
FPHA 16.0±1.4 -1.1 13.5
PHA 65.3±6.3 4.1 7.31×10 -5
Table 5 shows, the equilibrium potential absolute value of FPHA group is all greater than the equilibrium potential of PHA or gap is little with it, and prompting FPHA does not have tangible fluorine to discharge in neutral culture medium.
After the osseous tissue substitution material implants, material generation bone remodeling, this process comprises the degraded of material and the formation of new bone.The degraded of material comprises the decomposition and absorption of dissolving and the cells in vivo of material in body fluid to material, and hydroxyapatite class bone-grafting material dissolubility under neutral environment is lower, so main still through the degraded of osteoclast metabolism.Research shows that osteoclast is similar with the degraded of body internal skeleton mineral for the degraded of external calcium phosphate embedded material: osteoclast closely contacts the back with material and forms the enclosed area; Secrete hydrion in this differentiation and form local acid environment; PH value is lowered to 4~5, thereby causes material degradation.
Visible from experimental result; FPHA releasing fluoride ion not basically in neutral culture medium; And under sour environment, have tangible fluorine to discharge; Can think among the FPHA fluorion can along with osteoclast to its long-term degradation metabolism and slowly constant release come out, it is too fast and influence Expected Results the back rate of release can not occur implanting.
Three, zoopery
Key instrument equipment:
Superpure water machine 631UF, Sartorius, Germany
Vortex oscillation device VORTEX-GENIE2G560E, Scientific Industries, the U.S.
Slow machine Falcon50k, Silfradent, Italy
Annular is got bone drill Ф 8mm, Helmut Zepf, Germany
Micro-CT Inveon MM Gantry-STD CT camera, Siemens, Germany
Three-dimensional reconstruction system Inveon Acquisition Workplace V1.2, Siemens, Germany
The micro-CT pattern analysis Inveon Research Workplace V2.2.0 of system, Siemens, Germany
Computer automatic dehydration machine YABO600, Changzhou Ya Bo Electronics Equipment Co., Ltd, China
The microtome Leica SP1600 of sclerous tissues, Leica, Germany
Fluorescence is just being put microscope Axioskop40, Zeiss, Germany
IMAQ video camera AxioCam HRc, Zeiss, Germany
Image analysis system AxioVs40AC V4.5.0.0, Zeiss, Germany
Method:
Select 26 bull Sprague-Dawley rats, be divided into three groups at random, 6 of blank control group; Each 10 of PHA group and FPHA groups; Prepare the circular complete damaged model of thick single critical bone of diameter 8mm in each rat skull, the PHA group is implanted Os Sus domestica source hydroxyapatite, and (porcine hydroxyapatite is PHA) as contrast; FPHA group implant fluoridize Os Sus domestica source hydroxyapatite (fluorinated porcine hydroxyapatite, FPHA).FPHA in 0.25mol/L NaF solution soaking 24 hours, places Muffle furnace to be heated to 700 ℃ by PHA afterwards, and heating rate is 10 ℃, and keeps heating 3 hours at 700 ℃, and blank control group is not placed material, directly stitching.The experimental session animal does not have situation such as heating, infection, fluorosis to take place.Get half number animal in the 1st week of postoperative, the 4th week, the micro-CT live body scanning of the 8th week row for every group, put to death in the 8th week at last and get BIAO and BEN, utilize micro-CT pattern analysis system that three-dimensional reconstruction image is carried out the credit of bone morphometry and analyse.Second half animal is got the parallel microscopic CT scanning of BIAO and BEN in putting to death in the 4th week of postoperative, and BIAO and BEN is made the section of undecalcified sclerous tissues with reference to three-dimensional reconstruction image and in the descending histological observation of microscope, the result sees Figure 10 together with organizing in the 8th week.
(1) the micro-CT live body scanning three-dimensional reconstructed image of each processed group rat of different time points is shown in figure 10.
During the 1st week, the damaged edge of blank control group is smooth, does not see skeletonization.It is smooth that PHA group and FPHA organize damaged edge, and obvious embedded material image is not seen by damaged central authorities, and the part embedded material is located to develop on the edge of, and density is lower, does not link to each other with host bone.
During the 4th week, the damaged edge of blank control group owes smooth, at damaged edge the minute quantity skeletonization is arranged.PHA group and FPHA organize damaged edge original embedded material low-density shadow picture and disappear, and semilune area of new bone image appears in the bilateral edge, and density is high, closely links to each other with host bone, has the gap between part area of new bone and the host bone; There are 3 in 5 laboratory animals of FPHA group in the visible highdensity dystopy skeletonization image of damaged central authorities, do not link to each other with peripheral area of new bone.
During the 8th week, all processed group are not all seen damaged bony union.The damaged edge of blank control group owes smooth, and the edge skeletonization increases when all than the 4th slightly.PHA and FPHA organize damaged bilateral area of new bone to be increased on the basis of the 4th all skeletonization to some extent, and density does not have significant change, gap smaller between area of new bone and the host bone or disappearance.Area and density that FPHA organizes damaged central dystopy skeletonization increase, and with the semilune area of new bone at damaged edge the trend that is connected are arranged.
And all do not find the dystopy skeletonization in blank control group, PHA group.Therefore, the implantation of fluorion has the dystopy of promotion ossification.The dystopy skeletonization is meant in the middle of the soft tissue of noncontact osseous tissue, osteoblast differentiation occurs and forms osseous tissue.FPHA compares common biological apatite, has stronger dystopy ossification, explains that its induced dry-cell is divided into osteoblast and generates the effect of osseous tissue stronger.
(2) each processed group rat skull BIAO and BEN undecalcified sclerous tissues sections observation of different time points is like Figure 11,12, shown in 13 and 14.Wherein, the 4th when week all processed group defect of skull all do not see bony union.The blank control group defect is seen the loose fiber connective tissue, and there is a small amount of skeletonization at damaged edge.The down visible area of new bone of high power lens is formed by damaged edge, links to each other with host bone, and the area of new bone bone lacuna is bigger.FPHA group and PHA group defect have loose fiber connective tissue parcel embedded material, and the material multidigit is in damaged edge, and damaged central material is less, and area of new bone mainly appears at damaged edge embedded material and concentrates the place.Distinguishablely under the high power lens go out nattier blue osteoid and bolarious area of new bone holds embedded material, include a large amount of bone lacunas.There is area of new bone directly to link to each other between the embedded material, forms the bone trabecula shape structure of apertured.The host bone at area of new bone and damaged edge has the bone bridging to connect.Embedded material is not seen disintegrate.
All processed group defect of skull are not seen bony union yet during the 8th week.The blank control group defect is a large amount of feltwork connective tissues, and damaged edge skeletonization amount increases.The host bone at area of new bone and damaged edge can not be differentiated under the high power lens, and bone lacuna diminishes.FPHA group and PHA group defect have feltwork connective tissue parcel embedded material, and embedded material reduces when all than the 4th, and damaged edge skeletonization is more; Embedded material in the visible down three groups of experimental grouies of high power lens is all by the area of new bone parcel, and osteoid reduces.The interstructural hole of bone trabecula shape diminishes, and more shows fine and close.Have area of new bone directly to be connected to lamellar between material granule, bone lacuna reduces and diminishes, the material granule part disintegrate of area of new bone parcel.It is thus clear that FPHA has the skeletonization effect similar with clinical biogenic HA commonly used.
(3) the Micro CT live body of each processed group rat of different time points scanning area of new bone volume and surface area are shown in Figure 15 and 16.
During the 1st week, blank control group does not almost have area of new bone, and area of new bone volume and surface area data are almost 0, and the PHA group all has obvious area of new bone to generate with the FPHA group, and wherein the FPHA group is organized apparently higher than PHA.
4th, in 8 whens week,, blank control group, PHA group, FPHA group all detect the generation of area of new bone, and wherein area of new bone volume and surface area data are the FPHA group and are higher than blank control group and are higher than PHA and organize.
At variant time point, the FPHA group explains that all being higher than PHA group and blank control group aspect area of new bone volume and the area of new bone surface area FPHA osteogenic ability is higher than PHA.The comparison of relative the 4th, 8 all skeletonization amounts, FPHA has clear superiority when first week, and is visible, and it is more early faster that FPHA induces area of new bone to generate after implantation.

Claims (10)

1. the method for preparing that biogenic property is fluoridized the hydroxyapatite bone alternate material is characterized in that, may further comprise the steps:
(1) draw materials: the femoral inferior segment spongy bone to become pig is a raw material, is sawn into the bone piece, drying for standby;
(2) sintering: to the bone piece sintering that heats up, temperature to be sintered rises to 700~900 ℃ under air atmosphere, and sintering is 1~2 hour under this temperature range, cleans up after the room temperature cooling then, and drying obtains the Os Sus domestica hydroxyapatite;
(3) soak: the Os Sus domestica hydroxyapatite soaked in fluorine-containing solution 12~24 hours, took out drying;
(4) reacting by heating: will pass through Os Sus domestica hydroxyapatite after step (3) is handled and place and be warming up to 700~800 ℃ under the aerobic environment; And this temperature range internal heating 2~3 hours, cooling afterwash, drying; Pulverize obtains biogenic property and fluoridizes hydroxyapatite (FPHA) bone alternate material.
2. biogenic property according to claim 1 is fluoridized the method for preparing of hydroxyapatite bone alternate material, it is characterized in that, the fluorine-containing solution in the said step (3) adopts Fluorinse.
3. biogenic property according to claim 2 is fluoridized the method for preparing of hydroxyapatite bone alternate material, it is characterized in that, the concentration of described Fluorinse is 0.25~1mol/L.
4. biogenic property according to claim 2 is fluoridized the method for preparing of hydroxyapatite bone alternate material, it is characterized in that, the concentration of described Fluorinse is 0.25~0.5mol/L.
5. the method for preparing of fluoridizing the hydroxyapatite bone alternate material according to claim 2 or 3 or 4 described biogenic property is characterized in that, adopts excessive Fluorinse to soak the Os Sus domestica hydroxyapatite in the said step (3).
6. biogenic property according to claim 1 is fluoridized the method for preparing of hydroxyapatite bone alternate material, it is characterized in that, temperature is to rise to 700~900 ℃ from room temperature in the intensification sintering in the said step (2), and the heating rate of temperature is 10 ℃/min.
7. biogenic property according to claim 1 is fluoridized the method for preparing of hydroxyapatite bone alternate material, it is characterized in that, the heating rate of the heating-up temperature in the said step (3) is 10 ℃/min.
8. biogenic property according to claim 1 is fluoridized the method for preparing of hydroxyapatite bone alternate material, it is characterized in that, the drying that relates in said step (3) and (4) is being carried out below 80 ℃.
9. biogenic property according to claim 1 is fluoridized the method for preparing of hydroxyapatite bone alternate material, it is characterized in that, the volume size of the bone piece described in the said step (1) is 1 * 1 * 0.5cm 3
10. biogenic property according to claim 1 is fluoridized the method for preparing of hydroxyapatite bone alternate material, it is characterized in that, in the said step (1), said bone piece is at room temperature dry; In said step (1)~(4), after drying, all need semifinished or finished goods be preserved at a distance from wet.
CN201210254493.2A 2012-07-20 2012-07-20 Preparation method for biogenic fluorinated porcine hydroxyapatite (FPHA) bone substitution material Active CN102805879B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210254493.2A CN102805879B (en) 2012-07-20 2012-07-20 Preparation method for biogenic fluorinated porcine hydroxyapatite (FPHA) bone substitution material

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210254493.2A CN102805879B (en) 2012-07-20 2012-07-20 Preparation method for biogenic fluorinated porcine hydroxyapatite (FPHA) bone substitution material

Publications (2)

Publication Number Publication Date
CN102805879A true CN102805879A (en) 2012-12-05
CN102805879B CN102805879B (en) 2014-09-24

Family

ID=47229861

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210254493.2A Active CN102805879B (en) 2012-07-20 2012-07-20 Preparation method for biogenic fluorinated porcine hydroxyapatite (FPHA) bone substitution material

Country Status (1)

Country Link
CN (1) CN102805879B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103463681A (en) * 2013-09-16 2013-12-25 同济大学 Method for preparing biodegradable magnesium alloy surface modification fluoridated hydroxyapatite coating
CN111888522A (en) * 2020-09-22 2020-11-06 中山大学附属口腔医院 Periodontal regeneration material with immune regulation function and preparation method thereof
CN116040597A (en) * 2022-12-01 2023-05-02 中山大学附属口腔医院 Magnesium-doped nano-hydroxyapatite modified biological bone substitute material and preparation method and application thereof
CN116350842A (en) * 2023-03-30 2023-06-30 中山大学附属口腔医院 Application of biological hydroxyapatite combined with autologous periodontal ligament stem cells in immediate implantation of inflammation tooth extraction sites

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60106459A (en) * 1983-11-15 1985-06-11 三菱マテリアル株式会社 Calcium phosphate filler
WO2003089022A1 (en) * 2002-04-18 2003-10-30 University Of Florida Biomimetic organic/inorganic composites, processes for their production, and methods of use
CN1518522A (en) * 2001-06-22 2004-08-04 �����ɷ� Rod shaped apatite crystals with specific length-to-width ratio

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60106459A (en) * 1983-11-15 1985-06-11 三菱マテリアル株式会社 Calcium phosphate filler
CN1518522A (en) * 2001-06-22 2004-08-04 �����ɷ� Rod shaped apatite crystals with specific length-to-width ratio
WO2003089022A1 (en) * 2002-04-18 2003-10-30 University Of Florida Biomimetic organic/inorganic composites, processes for their production, and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAIBO QU ET.AL: "Effect of fluorine content on mechanical properties of sintered fluoridated hydroxyapatite", 《MATERIALS SCIENCE AND ENGINEERING C》, vol. 26, no. 1, 31 January 2006 (2006-01-31), pages 46 - 53 *
王冬赟等: "猪骨羟基磷灰石对MG63 细胞株生物学行为影响的实验研究", 《临床口腔医学杂志》, vol. 28, no. 5, 31 May 2012 (2012-05-31), pages 265 - 267 *
王芬等: "引氟含量对含氟羟基磷灰石纳米晶结构的影响", 《陶瓷学报》, vol. 27, no. 4, 31 December 2006 (2006-12-31), pages 393 - 395 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103463681A (en) * 2013-09-16 2013-12-25 同济大学 Method for preparing biodegradable magnesium alloy surface modification fluoridated hydroxyapatite coating
CN103463681B (en) * 2013-09-16 2015-01-14 同济大学 Method for preparing biodegradable magnesium alloy surface modification fluoridated hydroxyapatite coating
CN111888522A (en) * 2020-09-22 2020-11-06 中山大学附属口腔医院 Periodontal regeneration material with immune regulation function and preparation method thereof
CN116040597A (en) * 2022-12-01 2023-05-02 中山大学附属口腔医院 Magnesium-doped nano-hydroxyapatite modified biological bone substitute material and preparation method and application thereof
CN116040597B (en) * 2022-12-01 2023-09-29 中山大学附属口腔医院 Magnesium-doped nano-hydroxyapatite modified biological bone substitute material and preparation method and application thereof
CN116350842A (en) * 2023-03-30 2023-06-30 中山大学附属口腔医院 Application of biological hydroxyapatite combined with autologous periodontal ligament stem cells in immediate implantation of inflammation tooth extraction sites
CN116350842B (en) * 2023-03-30 2024-10-29 中山大学附属口腔医院 Application of biological hydroxyapatite combined with autologous periodontal ligament stem cells in immediate implantation of inflammation tooth extraction sites

Also Published As

Publication number Publication date
CN102805879B (en) 2014-09-24

Similar Documents

Publication Publication Date Title
CN106310374B (en) A kind of degradable magnesium contained phosphorite multiporous biological bracket
Bellucci et al. SBF assays, direct and indirect cell culture tests to evaluate the biological performance of bioglasses and bioglass-based composites: Three paradigmatic cases
KR102258806B1 (en) Regenerative medicine material and its manufacturing method and application
Fu et al. Characterization of a biodegradable coralline hydroxyapatite/calcium carbonate composite and its clinical implementation
CN108653819A (en) Short route prepares the method for porous bone- xenograft bone meal repair materials and bone renovating material obtained by this method
CN102805879B (en) Preparation method for biogenic fluorinated porcine hydroxyapatite (FPHA) bone substitution material
CN101274108B (en) Compound porous bracket and method of producing the same
CN102764450B (en) Cuttlebone transformation series porous composite bio-ceramic, its preparation method and application
Yadav et al. A comprehensive review on development of waste derived hydroxyapatite (HAp) for tissue engineering application
CN102145193A (en) Cuttlebone conversion series porous biological ceramics
Martin-Luengo et al. Biomaterials from beer manufacture waste for bone growth scaffolds
Venkatraman et al. Comparative investigation on antibacterial, biological and mechanical behaviour of monticellite and diopside derived from biowaste for bone regeneration
CN101596330A (en) α-half-H 2 O calcium sulphate/bata-tricalcium phosphate porous particle type cmposite artificial bone and preparation method thereof
CN109529119A (en) A kind of biological bone renovating material and preparation method thereof
Mehnath et al. Biomimetic and osteogenic natural HAP coated three dimensional implant for orthopaedic application
Horta et al. In vitro evaluation of natural hydroxyapatite from Osteoglossum bicirrhosum fish scales for biomedical application
CN105251050A (en) Preparation method of calcium phosphate-silk fibroin-zinc oxide composite coating
Deng et al. Preparation and characterization of porous HA/β-TCP biphasic calcium phosphate derived from butterfish bone
CN108578773A (en) Short route prepares the method for porous block xenogenesis bone renovating material and bone renovating material obtained by this method
CN103272283B (en) Mineralized bacterial cellulose three-dimensional porous bone tissue restoration scaffold preparation method
CN106421889A (en) Regenerative medical material and preparation method and application thereof
Yokota et al. In vivo evaluation of porous hydroxyapatite ceramics including bone minerals using pig model
Rana et al. Extraction and characterization of hdroxyapatite from bovine cortical bone and effect of radiatio
CN115845138A (en) Preparation method and application of high osteogenic activity bone repair material for promoting angiogenesis
Wang et al. Comparative evaluation of a biomimic collagen/hydroxyapatite/β-tricaleium phosphate scaffold in alveolar ridge preservation with Bio-Oss Collagen

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20170206

Address after: Guangzhou City, Guangdong province 510060 Cemetery Road No. 56

Patentee after: The Stomatologial Hospital of Zhongshan University

Address before: Planting the Stomatology Hospital Affiliated to Zhongshan University No. 56 Guangzhou City, Guangdong province 510060 Cemetery Road

Patentee before: Chen Zhuofan

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20170808

Address after: 4004 room 3, 519031 middle Bao Lu, Hengqin New District, Guangdong, Zhuhai, -553

Patentee after: Guangdong Phoenix equity investment management partnership (limited partnership)

Address before: Guangzhou City, Guangdong province 510060 Cemetery Road No. 56

Patentee before: The Stomatologial Hospital of Zhongshan University

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20171024

Address after: 510000 room eighth, building 804, building 11, Kaiyuan Avenue, Guangzhou hi tech Industrial Development Zone, Guangdong,

Patentee after: Guangdong honour Biotechnology Co., Ltd.

Address before: 4004 room 3, 519031 middle Bao Lu, Hengqin New District, Guangdong, Zhuhai, -553

Patentee before: Guangdong Phoenix equity investment management partnership (limited partnership)